Product Description: Naptumomab estafenatox, a tumor targeting superantigen (TTS), is a fusion protein containing. Naptumomab estafenatox stimulates the immune system to identify and kill tumour cells. Naptumomab estafenatox can be used for the research of refractory solid tumors such as renal cell carcinoma[1][2].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]Matthew K Robinson, et al. Naptumomab estafenatox: a new immunoconjugate. Expert Opin Biol Ther. 2010 Feb;10(2):273-9./[2]Tim Eisen, et al. Naptumomab estafenatox: targeted immunotherapy with a novel immunotoxin. Curr Oncol Rep. 2014 Feb;16(2):370.
CAS Number: 1412892-09-1
Molecular Weight: N/A
Compound Purity: 99.90
Research Area: Cancer; Inflammation/Immunology
Solubility: H2O
Target: Others